The Roche Group delivered revenue of CHF 61.5 billion ($79.2 billion) in 2025 – an increase of 2% in Swiss francs and 7% at constant exchange rates and driven by five products covering a diverse group of diseases. The revenue was sufficiently large to offset the company’s loss of income in the US from six legacy products, including Herceptin, the world’s first targeted therapy for cancer.
